Targeting the tumor mutanome for personalized vaccination therapy

 Abstract

Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
768 - 769
doi
10.4161/onci.19727
Type
Author's View
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
Targeting the tumor mutanome for personalized vaccination therapy